Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Hoft

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
Frontiers in Immunology|February 6, 2023
The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studiesJohannes B Goll, Steven E Bosinger, Travis L Jensen, et al.
Vaccines|July 30, 2020
Alterations in the Human Plasma Lipidome in Response to Tularemia VaccinationKristal M Maner-Smith, Johannes B Goll, Manoj Khadka, et al.
The Journal of Infectious Diseases|July 19, 2023
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical TrialHana M El Sahly, Inci Yildirim, Sharon E Frey, et al.
Frontiers in Immunology|September 14, 2023
Identification of immunodominant T cell epitopes induced by natural Zika virus infectionChristopher S Eickhoff, Krystal A Meza, Frances E Terry, et al.
Ebiomedicine|February 12, 2022
Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studiesAnele Gela, Melissa Murphy, Miguel Rodo, et al.
The Journal of Infectious Diseases|January 26, 2023
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy AdultsJustin R Ortiz, David I Bernstein, Daniel F Hoft, et al.
Ebiomedicine|June 21, 2016
Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 TrialDaniel F Hoft, Azra Blazevic, Asmir Selimovic, et al.
The Journal of Infectious Diseases|November 29, 2023
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In VivoAzra Blazevic, Rachel L Edwards, Mei Xia, et al.
Vaccine|February 25, 2026
The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adultsJennifer A Whitaker, Paulina A Rebolledo, Getahun Abate, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Frontiers in Immunology|February 6, 2023
The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studiesJohannes B Goll, Steven E Bosinger, Travis L Jensen, et al.
Vaccines|July 30, 2020
Alterations in the Human Plasma Lipidome in Response to Tularemia VaccinationKristal M Maner-Smith, Johannes B Goll, Manoj Khadka, et al.
The Journal of Infectious Diseases|July 19, 2023
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical TrialHana M El Sahly, Inci Yildirim, Sharon E Frey, et al.
Frontiers in Immunology|September 14, 2023
Identification of immunodominant T cell epitopes induced by natural Zika virus infectionChristopher S Eickhoff, Krystal A Meza, Frances E Terry, et al.
Ebiomedicine|February 12, 2022
Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studiesAnele Gela, Melissa Murphy, Miguel Rodo, et al.
The Journal of Infectious Diseases|January 26, 2023
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy AdultsJustin R Ortiz, David I Bernstein, Daniel F Hoft, et al.
Ebiomedicine|June 21, 2016
Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 TrialDaniel F Hoft, Azra Blazevic, Asmir Selimovic, et al.
The Journal of Infectious Diseases|November 29, 2023
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In VivoAzra Blazevic, Rachel L Edwards, Mei Xia, et al.
Vaccine|February 25, 2026
The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adultsJennifer A Whitaker, Paulina A Rebolledo, Getahun Abate, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Pageof 13